Search Press releases Keywords From To 8 Jul 2026 UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026 Read More 17 Jun 2026 UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d) Read More 17 Jun 2026 UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline Read More 5 Jun 2026 New EULAR 2026 data show CIMZIA[®] (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels Read More 4 Jun 2026 EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus Read More 3 Jun 2026 BIMZELX[®](bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
